PT  - JOURNAL ARTICLE
AU  - Sahahjpal, Nikhil Shri
AU  - Hon, Ephrem Chin Lip
AU  - Dallaire, Stephanie
AU  - Williams, Colin
AU  - Ananth, Sudha
AU  - Mondal, Ashis K
AU  - Rojiani, Amyn M
AU  - Hegde, Madhuri
AU  - Kolhe, Ravindra
TI  - COVID-19 RT-PCR diagnostic assay sensitivity and SARS-CoV-2 transmission: A missing link?
AID  - 10.1101/2021.03.24.21254271
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.24.21254271
4099  - http://medrxiv.org/content/early/2021/03/26/2021.03.24.21254271.short
4100  - http://medrxiv.org/content/early/2021/03/26/2021.03.24.21254271.full
AB  - Background The sensitivity of commercially available RT-PCR assays varies over 10,000 fold, ranging from 10 to 20,000 viral copies/ml. The reporting of high Ct value results has been under scrutiny, as the clinical significance of these values is not yet completely understood. The early detection of infected individuals (high Ct results) in the pre-symptomatic phase of the disease using highly sensitive RT-PCR methods has been argued as a strategy to prevent transmission, while on the contrary, the reporting of high Ct has been criticized as false-positive results causing unnecessary testing and having several negative implications. The purpose of this study was to verify the presence of SARS-CoV-2 genomes in samples with a wide range of RT-PCR Ct values including samples with high Ct (37 to 42) using next-generation sequencing (NGS).Methods The study evaluated a total of 547 previously positive samples tested with the PerkinElmer® New Coronavirus Nucleic Acid Detection RT-PCR kit. The samples included in this study ranged from Ct values of 17-42, with 44 samples having a Ct > 37. Of the 547 samples, 149 were sequenced using PerkinElmer NEXTFLEX Variant-Seq SARS-CoV2 assay on NovaSeq 6000, and 398 samples were sequenced using Illumina SARS-CoV-2 respiratory viral panel kits using the NextSeq 500/550 system.Results Between the two clinical laboratories, a total of ∼1.95 million samples were tested using the FDA-EUA PerkinElmer® New Coronavirus RT-PCR assay. Of the 1.95 million samples, ∼1.72 million were negative, ∼250,000 positive, and ∼16,500 in the range of 37-42. Of the 547 samples sequenced, the percentage of sequencing reads that aligned to the SARS-CoV-2 Wuhan-hu-1 reference genome (NC_045512.2) ranged from 25.5% to 99.69%. All samples sequenced showed high sequence specificity to the SARS-CoV-2 virus. Low Ct samples showed complete uniform coverage across the entire 29kb SAR-CoV-2 genome. The average coverage in samples with high Ct (>37) was found to be 55.5% (range 16.1-99.2%). However, as sample Ct increased, a gradual decrease in coverage uniformity was observed for few samples.Conclusion This study demonstrates for the first time that the viral RNA is present in the high Ct value range of 37-42 and the sequence is unique to SARS-CoV-2 confirmed using two separate sequencing assays. This confirms that the detected Ct values are reflective of the presence of the SARS-CoV-2 virus and they are not an artifact or contamination. In light of the recent work highlighting the majority of transmission being pre-symptomatic/ asymptomatic, and high Ct results being observed at both the early and late phases of infection warrants further investigation into the clinical utility of high Ct results to curtail the spread of the virus.Competing Interest StatementRK has received honoraria, travel funding, and research support from Illumina, Asuragen, QIAGEN, PerKinElmer Inc. and BMS. EH, SD and MH are salaried employees of PerkinElmer Inc. and MH holds stock options at PerkinElmer Inc.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The samples were processed under an approved HAC by the IRB Committee A (IRB REGISTRATION # 611298), Augusta University, GA. Based on the IRB approval, all PHI was removed and all data was anonymized before accessing for the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data has been included in the manuscript.